glycine has been researched along with AL Amyloidosis in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 9.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 5.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| " We report outcomes of 40 patients with relapsed AL amyloidosis treated with ixazomib + lenalidomide + dexamethasone (IRd)." | 3.96 | Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. ( Cheesman, S; Cohen, OC; Fontana, M; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Martinez-Naharro, A; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Wechalekar, AD; Whelan, CJ; Yong, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenbaum, CA | 1 |
| Özbek, U | 1 |
| Sanchez, L | 1 |
| Lagdameo, J | 1 |
| Abrahams, A | 1 |
| Hassoun, H | 1 |
| Lahoud, O | 1 |
| Niesvizky, R | 1 |
| Landau, HJ | 2 |
| Osman, K | 1 |
| Premkumar, V | 1 |
| Comenzo, R | 1 |
| Lentzsch, S | 1 |
| Cohen, OC | 1 |
| Sharpley, F | 1 |
| Gillmore, JD | 1 |
| Lachmann, HJ | 1 |
| Sachchithanantham, S | 1 |
| Mahmood, S | 1 |
| Fontana, M | 1 |
| Whelan, CJ | 1 |
| Martinez-Naharro, A | 1 |
| Kyriakou, C | 1 |
| Rabin, N | 1 |
| Popat, R | 1 |
| Yong, K | 1 |
| Cheesman, S | 1 |
| Shah, R | 1 |
| Hawkins, PN | 1 |
| Wechalekar, AD | 2 |
| Dispenzieri, A | 1 |
| Kastritis, E | 1 |
| Schönland, SO | 1 |
| Kim, K | 1 |
| Sanchorawala, V | 1 |
| Kwok, F | 1 |
| Suzuki, K | 1 |
| Comenzo, RL | 1 |
| Berg, D | 1 |
| Liu, G | 1 |
| Kumar, A | 1 |
| Faller, DV | 1 |
| Merlini, G | 1 |
| Joseph, NS | 1 |
| Kaufman, JL | 1 |
| Smolewski, P | 1 |
| Rydygier, D | 1 |
2 reviews available for glycine and AL Amyloidosis
| Article | Year |
|---|---|
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunog | 2018 |
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investi | 2019 |
2 trials available for glycine and AL Amyloidosis
| Article | Year |
|---|---|
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.
Topics: Boron Compounds; Cyclophosphamide; Dexamethasone; Glycine; Humans; Immunoglobulin Light-chain Amyloi | 2022 |
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyc | 2022 |
2 other studies available for glycine and AL Amyloidosis
| Article | Year |
|---|---|
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Bridged Bicyclo C | 2019 |
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dex | 2020 |